Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 56Carcinoma, Hepatocellular 43Carcinoma, Non-Small-Cell Lung 23Small Cell Lung Carcinoma 19Ovarian Neoplasms 18Colorectal Neoplasms 18Breast Neoplasms 17Sarcoma 14Neoplasms 14Triple Negative Breast Neoplasms 13Nasopharyngeal Carcinoma 11Esophageal Squamous Cell Carcinoma 10Cholangiocarcinoma 10Osteosarcoma 9Lung Neoplasms 9Esophageal Neoplasms 9Neoplasm Metastasis 8Biliary Tract Neoplasms 8Advanced Gastric Cancer 8Uterine Cervical Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Recurrence 6Pancreatic Neoplasms 6Head and Neck Neoplasms 6Thyroid Neoplasms 4Solid Tumor 4Melanoma 4Liver Neoplasms 4Glioma 4Drug-Related Side Effects and Adverse Reactions 4

Interventions

camrelizumab 2apatinib 2Ramucirumab 2trifluridine tipiracil drug combination 1tipiracil 1irinotecan sucrosofate 1Trifluridine 1S 1 (combination) 1Fluorouracil 1Docetaxel 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Metastatic Gastric Adenocarcinoma × apatinib × Clear all
NCT05342389 2022-04-22

Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer

Sixth Affiliated Hospital, Sun Yat-sen University

Phase 2 Unknown
68 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

NCT04781686 2021-05-17

Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer

Zhongnan Hospital

Phase 2 Unknown
35 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡